The company plans to use the financing to advance TT-20, its lead drug candidate for the treatment of white matter brain injury in preterm infants, according to a Dec. 13 Tellus news release.
Perceptive Xontogeny Venture Fund led the series A financing round and the company’s earlier seed round.
